{"id":977067,"date":"2026-06-30T09:35:09","date_gmt":"2026-06-30T13:35:09","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/hcw-biologics-regained-compliance-with-bid-price-rule-per-nasdaq-compliance-letter\/"},"modified":"2026-06-30T09:35:09","modified_gmt":"2026-06-30T13:35:09","slug":"hcw-biologics-regained-compliance-with-bid-price-rule-per-nasdaq-compliance-letter","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/hcw-biologics-regained-compliance-with-bid-price-rule-per-nasdaq-compliance-letter\/","title":{"rendered":"HCW Biologics Regained Compliance with Bid Price Rule Per Nasdaq Compliance Letter"},"content":{"rendered":"<h2>\nCompany now compliant with all continued listing rules for Nasdaq<br \/>\n<\/h2>\n<div class=\"mw_release\">\n<p align=\"justify\">MIRAMAR, Fla., June  30, 2026  (GLOBE NEWSWIRE) &#8212; HCW Biologics Inc. (the \u201cCompany\u201d or \u201cHCW Biologics\u201d) (Nasdaq: HCWB), a U.S.-based clinical-stage biopharmaceutical company developing transformative fusion immunotherapeutics to support or treat diseases promoted by chronic inflammation, focusing on autoimmune disorders and other inflammatory diseases, cancer and senescence-associated dysplasia, today reported that, on June 29, 2026, the Nasdaq Hearings Panel (the \u201cPanel\u201d) of The Nasdaq Stock Market LLC (\u201cNasdaq\u201d or the \u201cExchange\u201d) found that the Company regained compliance with Listing Rule 5550(a)(2), the \u201cBid Price Rule,\u201d per the terms set forth in the Panel\u2019s decision letter dated May 29, 2026, as amended, and is subject to a mandatory monitoring period through June 17, 2027.<\/p>\n<p align=\"justify\">To ensure long-term compliance with the Bid Price Rule, the Company will effect a reverse stock split at a one-for-six ratio on June 30, 2026.<\/p>\n<p align=\"justify\">\n        <strong>About HCW Biologics:<\/strong>\n      <\/p>\n<p align=\"justify\">HCW Biologics Inc. (the \u201cCompany\u201d) (NASDAQ: HCWB) is a clinical-stage biopharmaceutical company developing transformative fusion immunotherapeutics to treat diseases promoted by chronic inflammation, including autoimmune diseases, cancer, and senescence-associated dysplasia. The Company\u2019s immunotherapeutics represent a new class of drugs that it believes have the potential to fundamentally change the treatment of proinflammatory and senescence-associated diseases and conditions that are promoted by chronic inflammation \u2014and in doing so, improve patients\u2019 quality of life and possibly extend longevity. A key aspect of the Company\u2019s clinical development and financing strategy is to focus on its business development programs. See the Company Pipeline at <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=ooWjrBM6o1qhGF8FZco9wYj1rUwUAx-dY9DurKvExtiryAdpHpR0LqcJIy-uDCUlBcgUrfWX56fXdLUi-3g1JCHuAWMDOvwNE0TNPb0H6DBLdo3CsNNznC-b832zZIpz\" rel=\"nofollow\" target=\"_blank\">https:\/\/hcwbiologics.com\/pipeline\/<\/a><\/p>\n<p align=\"justify\">\n        <strong>Forward-Looking Statements<\/strong>:<\/p>\n<p align=\"justify\">This press release contains forward-looking statements as that term is defined in Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Statements in this press release that are not purely historical are forward-looking statements. Such forward-looking statements include, among other things, statements relating to the timing, consummation, and impact of the reverse stock split, the Company\u2019s ability to maintain long-term compliance with Nasdaq\u2019s minimum bid price requirement, and the actions of third parties, including Equiniti, the Company\u2019s transfer agent, with respect to the reverse stock split. Actual results could differ from those projected in any forward-looking statement due to numerous factors. Such factors include, among others, our ability to maintain compliance with Nasdaq\u2019s continued listing rules. These forward-looking statements are made as of the date of this press release, and we assume no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements, except as required by law. Investors should consult all of the information set forth herein and should also refer to the risk factor disclosure set forth in the reports and other documents we file with the Securities and Exchange Commission, or the SEC, available at www.sec.gov, including, without limitation, the Company\u2019s most recent Annual Report on Form 10-K filed on March 31, 2026, and other SEC filings.<\/p>\n<p align=\"justify\">\n        <strong>Company Contact:<\/strong>\n      <\/p>\n<p align=\"justify\">Rebecca Byam<br \/>CFO<br \/>HCW Biologics Inc.<br \/>rebeccabyam@hcwbiologics.com<\/p>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTc1NDU1NSM3NjgzODc3IzIyMTAxOTg=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml.globenewswire.com\/media\/MDQwMzU2ZmItODFhYi00ZWQ2LTgwY2UtMmY5OTA0MWY1Mjc3LTEyMjE3NTEtMjAyNi0wNi0zMC1lbg==\/tiny\/HCW-Biologics-Inc.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Company now compliant with all continued listing rules for Nasdaq MIRAMAR, Fla., June 30, 2026 (GLOBE NEWSWIRE) &#8212; HCW Biologics Inc. (the \u201cCompany\u201d or \u201cHCW Biologics\u201d) (Nasdaq: HCWB), a U.S.-based clinical-stage biopharmaceutical company developing transformative fusion immunotherapeutics to support or treat diseases promoted by chronic inflammation, focusing on autoimmune disorders and other inflammatory diseases, cancer and senescence-associated dysplasia, today reported that, on June 29, 2026, the Nasdaq Hearings Panel (the \u201cPanel\u201d) of The Nasdaq Stock Market LLC (\u201cNasdaq\u201d or the \u201cExchange\u201d) found that the Company regained compliance with Listing Rule 5550(a)(2), the \u201cBid Price Rule,\u201d per the terms set forth in the Panel\u2019s decision letter dated May 29, 2026, as amended, and is subject to a mandatory monitoring period through &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/hcw-biologics-regained-compliance-with-bid-price-rule-per-nasdaq-compliance-letter\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;HCW Biologics Regained Compliance with Bid Price Rule Per Nasdaq Compliance Letter&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-977067","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.9 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>HCW Biologics Regained Compliance with Bid Price Rule Per Nasdaq Compliance Letter - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/hcw-biologics-regained-compliance-with-bid-price-rule-per-nasdaq-compliance-letter\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"HCW Biologics Regained Compliance with Bid Price Rule Per Nasdaq Compliance Letter - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Company now compliant with all continued listing rules for Nasdaq MIRAMAR, Fla., June 30, 2026 (GLOBE NEWSWIRE) &#8212; HCW Biologics Inc. (the \u201cCompany\u201d or \u201cHCW Biologics\u201d) (Nasdaq: HCWB), a U.S.-based clinical-stage biopharmaceutical company developing transformative fusion immunotherapeutics to support or treat diseases promoted by chronic inflammation, focusing on autoimmune disorders and other inflammatory diseases, cancer and senescence-associated dysplasia, today reported that, on June 29, 2026, the Nasdaq Hearings Panel (the \u201cPanel\u201d) of The Nasdaq Stock Market LLC (\u201cNasdaq\u201d or the \u201cExchange\u201d) found that the Company regained compliance with Listing Rule 5550(a)(2), the \u201cBid Price Rule,\u201d per the terms set forth in the Panel\u2019s decision letter dated May 29, 2026, as amended, and is subject to a mandatory monitoring period through &hellip; Continue reading &quot;HCW Biologics Regained Compliance with Bid Price Rule Per Nasdaq Compliance Letter&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/hcw-biologics-regained-compliance-with-bid-price-rule-per-nasdaq-compliance-letter\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2026-06-30T13:35:09+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTc1NDU1NSM3NjgzODc3IzIyMTAxOTg=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/hcw-biologics-regained-compliance-with-bid-price-rule-per-nasdaq-compliance-letter\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/hcw-biologics-regained-compliance-with-bid-price-rule-per-nasdaq-compliance-letter\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"HCW Biologics Regained Compliance with Bid Price Rule Per Nasdaq Compliance Letter\",\"datePublished\":\"2026-06-30T13:35:09+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/hcw-biologics-regained-compliance-with-bid-price-rule-per-nasdaq-compliance-letter\\\/\"},\"wordCount\":512,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/hcw-biologics-regained-compliance-with-bid-price-rule-per-nasdaq-compliance-letter\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTc1NDU1NSM3NjgzODc3IzIyMTAxOTg=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/hcw-biologics-regained-compliance-with-bid-price-rule-per-nasdaq-compliance-letter\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/hcw-biologics-regained-compliance-with-bid-price-rule-per-nasdaq-compliance-letter\\\/\",\"name\":\"HCW Biologics Regained Compliance with Bid Price Rule Per Nasdaq Compliance Letter - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/hcw-biologics-regained-compliance-with-bid-price-rule-per-nasdaq-compliance-letter\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/hcw-biologics-regained-compliance-with-bid-price-rule-per-nasdaq-compliance-letter\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTc1NDU1NSM3NjgzODc3IzIyMTAxOTg=\",\"datePublished\":\"2026-06-30T13:35:09+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/hcw-biologics-regained-compliance-with-bid-price-rule-per-nasdaq-compliance-letter\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/hcw-biologics-regained-compliance-with-bid-price-rule-per-nasdaq-compliance-letter\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/hcw-biologics-regained-compliance-with-bid-price-rule-per-nasdaq-compliance-letter\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTc1NDU1NSM3NjgzODc3IzIyMTAxOTg=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTc1NDU1NSM3NjgzODc3IzIyMTAxOTg=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/hcw-biologics-regained-compliance-with-bid-price-rule-per-nasdaq-compliance-letter\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"HCW Biologics Regained Compliance with Bid Price Rule Per Nasdaq Compliance Letter\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"HCW Biologics Regained Compliance with Bid Price Rule Per Nasdaq Compliance Letter - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/hcw-biologics-regained-compliance-with-bid-price-rule-per-nasdaq-compliance-letter\/","og_locale":"en_US","og_type":"article","og_title":"HCW Biologics Regained Compliance with Bid Price Rule Per Nasdaq Compliance Letter - Market Newsdesk","og_description":"Company now compliant with all continued listing rules for Nasdaq MIRAMAR, Fla., June 30, 2026 (GLOBE NEWSWIRE) &#8212; HCW Biologics Inc. (the \u201cCompany\u201d or \u201cHCW Biologics\u201d) (Nasdaq: HCWB), a U.S.-based clinical-stage biopharmaceutical company developing transformative fusion immunotherapeutics to support or treat diseases promoted by chronic inflammation, focusing on autoimmune disorders and other inflammatory diseases, cancer and senescence-associated dysplasia, today reported that, on June 29, 2026, the Nasdaq Hearings Panel (the \u201cPanel\u201d) of The Nasdaq Stock Market LLC (\u201cNasdaq\u201d or the \u201cExchange\u201d) found that the Company regained compliance with Listing Rule 5550(a)(2), the \u201cBid Price Rule,\u201d per the terms set forth in the Panel\u2019s decision letter dated May 29, 2026, as amended, and is subject to a mandatory monitoring period through &hellip; Continue reading \"HCW Biologics Regained Compliance with Bid Price Rule Per Nasdaq Compliance Letter\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/hcw-biologics-regained-compliance-with-bid-price-rule-per-nasdaq-compliance-letter\/","og_site_name":"Market Newsdesk","article_published_time":"2026-06-30T13:35:09+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTc1NDU1NSM3NjgzODc3IzIyMTAxOTg=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/hcw-biologics-regained-compliance-with-bid-price-rule-per-nasdaq-compliance-letter\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/hcw-biologics-regained-compliance-with-bid-price-rule-per-nasdaq-compliance-letter\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"HCW Biologics Regained Compliance with Bid Price Rule Per Nasdaq Compliance Letter","datePublished":"2026-06-30T13:35:09+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/hcw-biologics-regained-compliance-with-bid-price-rule-per-nasdaq-compliance-letter\/"},"wordCount":512,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/hcw-biologics-regained-compliance-with-bid-price-rule-per-nasdaq-compliance-letter\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTc1NDU1NSM3NjgzODc3IzIyMTAxOTg=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/hcw-biologics-regained-compliance-with-bid-price-rule-per-nasdaq-compliance-letter\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/hcw-biologics-regained-compliance-with-bid-price-rule-per-nasdaq-compliance-letter\/","name":"HCW Biologics Regained Compliance with Bid Price Rule Per Nasdaq Compliance Letter - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/hcw-biologics-regained-compliance-with-bid-price-rule-per-nasdaq-compliance-letter\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/hcw-biologics-regained-compliance-with-bid-price-rule-per-nasdaq-compliance-letter\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTc1NDU1NSM3NjgzODc3IzIyMTAxOTg=","datePublished":"2026-06-30T13:35:09+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/hcw-biologics-regained-compliance-with-bid-price-rule-per-nasdaq-compliance-letter\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/hcw-biologics-regained-compliance-with-bid-price-rule-per-nasdaq-compliance-letter\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/hcw-biologics-regained-compliance-with-bid-price-rule-per-nasdaq-compliance-letter\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTc1NDU1NSM3NjgzODc3IzIyMTAxOTg=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTc1NDU1NSM3NjgzODc3IzIyMTAxOTg="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/hcw-biologics-regained-compliance-with-bid-price-rule-per-nasdaq-compliance-letter\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"HCW Biologics Regained Compliance with Bid Price Rule Per Nasdaq Compliance Letter"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/977067","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=977067"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/977067\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=977067"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=977067"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=977067"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}